A Phase 1B/2, Multicenter, Open Label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec (T-Vec) and Ipilimumab (Ipi) Versus Ipi Alone in Previously Untreated, Unresected, Stage Iiib, Iiic, and Iv Melanoma

Open Label ◽

Safety And Efficacy ◽

Phase 1B ◽

Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-1-s1-p84 ◽

2013 ◽

Vol 1 (S1) ◽

Cited By ~ 4

Author(s):

Igor Puzanov ◽

Mohammed Milhem ◽

Robert Andtbacka ◽

David Minor ◽

Omid Hamid ◽

...

Keyword(s):

Phase 1 ◽

Stage Iiib ◽

Open Label ◽

Safety And Efficacy ◽

Phase 1B ◽

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

Annals of Oncology ◽

10.1093/annonc/mdw379.04 ◽

2016 ◽

Vol 27 ◽

pp. vi380 ◽

Cited By ~ 10

Author(s):

J. Chesney ◽

F. Collichio ◽

R.H.I. Andtbacka ◽

I. Puzanov ◽

J. Glaspy ◽

...

Keyword(s):

Stage Iiib ◽

Phase 2 ◽

Open Label ◽

Safety And Efficacy ◽

Phase 2 Study ◽

Open Label Phase

Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

10.1200/jco.2014.32.15_suppl.9029 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 9029-9029 ◽

Cited By ~ 33

Author(s):

Igor Puzanov ◽

Mohammed M. Milhem ◽

Robert Hans Ingemar Andtbacka ◽

David R. Minor ◽

Omid Hamid ◽

...

Keyword(s):

Multicenter Trial ◽

Stage Iiib ◽

Primary Analysis ◽

Safety And Efficacy ◽

Phase 1B

A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).

10.1200/jco.2018.36.15_suppl.tps3105 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS3105-TPS3105 ◽

Cited By ~ 1

Author(s):

J. Randolph Hecht ◽

Aleix Prat ◽

Miklos Pless ◽

Antonio Cubillo ◽

Aitana Calvo ◽

...

Keyword(s):

Liver Tumors ◽

Open Label ◽

Phase 1B ◽

Open Label Trial ◽

Metastatic Liver Tumors ◽

Metastatic Liver

A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.

10.1200/jco.2015.33.15_suppl.tps9081 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS9081-TPS9081 ◽

Cited By ~ 7

Author(s):

Antoni Ribas ◽

Igor Puzanov ◽

Thomas Gajewski ◽

Georgina V. Long ◽

Reinhard Dummer ◽

...

Keyword(s):

Stage Iiib ◽

Open Label ◽

Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL).

10.1200/jco.2015.33.15_suppl.tps9094 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS9094-TPS9094 ◽

Cited By ~ 6

Author(s):

Robert Hans Ingemar Andtbacka ◽

Michael Chastain ◽

Ai Li ◽

Mark Shilkrut ◽

Merrick I. Ross

Keyword(s):

Neoadjuvant Treatment ◽

Stage Iiib ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-3-s2-p181 ◽

2015 ◽

Vol 3 (S2) ◽

Cited By ~ 14

Author(s):

Georgina V Long ◽

Reinhard Dummer ◽

Antoni Ribas ◽

Igor Puzanov ◽

Olivier Michielin ◽

...

Keyword(s):

Phase I ◽

Stage Iiib ◽

Open Label ◽

Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma

Annals of Oncology ◽

10.1093/annonc/mdz394.063 ◽

2019 ◽

Vol 30 ◽

pp. v903 ◽

Cited By ~ 2

Author(s):

R. Dummer ◽

D.E. Gyorki ◽

J. Hyngstrom ◽

A. Berger ◽

R. Conry ◽

...

Keyword(s):

Phase Ii ◽

Stage Iiib ◽

Efficacy And Safety ◽

Open Label ◽

Abstract B13: A phase 2, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs. surgery for resectable stage IIIB-IVM1a melanoma

10.1158/1538-7445.mel2014-b13 ◽

2015 ◽

Cited By ~ 1

Author(s):

Robert HI Andtbacka ◽

Mohamed Shabooti ◽

Ai Li ◽

Michael Chastain ◽

Mark Shilkrut

Keyword(s):

Neoadjuvant Treatment ◽

Stage Iiib ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Case Medical Research ◽

10.31525/ct1-nct04113616 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Low Dose ◽

Open Label ◽

Safety And Efficacy ◽

Multicenter Phase ◽

Phase 1B ◽

Low Dose Cytarabine ◽

Acute Myeloid